Secondary Stroke Prevention: A Population-Based Cohort Study on Anticoagulation and Antiplatelet Treatments, and the Risk of Death or Recurrence
| dc.rights.license | open | en_US |
| dc.contributor.author | FAURE, M. | |
| dc.contributor.author | CASTILLOUX, A. M. | |
| dc.contributor.author | LILLO-LE-LOUET, A. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BEGAUD, Bernard | |
| dc.contributor.author | MORIDE, Y. | |
| dc.date.accessioned | 2021-01-25T10:34:55Z | |
| dc.date.available | 2021-01-25T10:34:55Z | |
| dc.date.issued | 2020 | |
| dc.identifier.issn | 1532-6535 (Electronic) 0009-9236 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/25978 | |
| dc.description.abstractEn | Using claims databases of a public healthcare program (Quebec) for the years 2010–2013, we conducted a cohort study of patients with acute ischemic stroke (AIS) to describe secondary prevention treatments and determine how they stood against practice guidelines. We compared the risk of death or AIS recurrence over 1 year in patients treated with anticoagulants, antiplatelets, and/or other cardiovascular drugs. In the month after discharge, 44.3% of the patients did not receive the recommended treatment and > 20% did not have any treatment. Untreated patients were younger, had less comorbidities, and a more severe AIS. Anticoagulants and antiplatelets were associated with a reduced risk of death or recurrence (hazard ratio (HR) 0.27; 95% confidence interval (CI) 0.20–0.36 and HR 0.25; 95% CI 0.16–0.38, respectively) compared with the untreated group. Effect size was similar for the other treatments. Findings confirm treatment benefits shown in clinical trials and emphasize the importance of AIS secondary prevention. | |
| dc.language.iso | EN | en_US |
| dc.subject | PharmacoEpi-Drugs | |
| dc.title.en | Secondary Stroke Prevention: A Population-Based Cohort Study on Anticoagulation and Antiplatelet Treatments, and the Risk of Death or Recurrence | |
| dc.title.alternative | Clin Pharmacol Ther | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1002/cpt.1625 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 31502245 | en_US |
| bordeaux.journal | Clinical Pharmacology and Therapeutics | en_US |
| bordeaux.page | 443-451 | en_US |
| bordeaux.volume | 107 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 2 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | PharmacoEpi-Drugs | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03120031 | |
| hal.version | 1 | |
| hal.date.transferred | 2021-01-25T10:34:59Z | |
| hal.export | true | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Pharmacology%20and%20Therapeutics&rft.date=2020&rft.volume=107&rft.issue=2&rft.spage=443-451&rft.epage=443-451&rft.eissn=1532-6535%20(Electronic)%200009-9236%20(Linking)&rft.issn=1532-6535%20(Electronic)%200009-9236%20(Linking)&rft.au=FAURE,%20M.&CASTILLOUX,%20A.%20M.&LILLO-LE-LOUET,%20A.&BEGAUD,%20Bernard&MORIDE,%20Y.&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||